An Extended Dosing Regimen of Epoetin Alfa 60,000 Units Every 2 Weeks in Anemic Patients with Cancer Receiving Chemotherapy
- 30 September 2007
- journal article
- Published by Elsevier BV in Supportive Cancer Therapy
- Vol. 4 (4), 225-232
- https://doi.org/10.3816/sct.2007.n.019
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapySupportive Care in Cancer, 2007
- Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 μg Every 2 Weeks) in Anemic Patients with Cancer Receiving ChemotherapyThe Oncologist, 2005
- Weekly Epoetin Alfa Maintains Hemoglobin, Improves Quality of Life, and Reduces Transfusion in Breast Cancer Patients Receiving ChemotherapyJournal of Clinical Oncology, 2005
- Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving ChemotherapyJournal of Clinical Oncology, 2005
- Treatment of cancer-related anemia with epoetin alfa: a reviewCancer Treatment Reviews, 2004
- The Evolving Role of Epoetin Alfa in Cancer TherapyThe Oncologist, 2004
- New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical ApplicationsThe Oncologist, 2003
- Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly DosingJournal of Clinical Oncology, 2001
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.Journal of Clinical Oncology, 1998
- Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.Journal of Clinical Oncology, 1997